TRAX First Tracks Biotherapeutics Inc.

$TRAX also releasing data tomorrow morning. First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 "will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT."

Canaccord Genuity🏁 $TRAX and said -- We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12-month price target of $50. $ANAB ENTO FBRX TAK SNY TEVA $EPRX AZN BMY PHAT ABBV GILD REGN PFE LLY Canaccord Genuity added—The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis (EoE) in 3Q27. The remaining 5% of our valuation comes from rosnilimab, which recently reported positive Phase IIb data in rheumatoid arthritis but is paused pending a partner for Phase III development.

$TRAX those results you’d think we’d be at 50 but I’ll snatch up any dips this company’s a money maker

$TRAX Argenix acquired Forte Biosciences for $2.2B. TRAX Celiac drug looks to be superior along with its pipeline. Current TRAX market cap is just under $1B. It's inevitable this one will also be bought. Buy it and hold. Should be an easy double.

$TRAX 🏥 First Tracks Biotherapeutics Inc. announced positive top-line results for ANB033 in a gluten-challenge study in celiac disease, with statistically significant protective effects on gluten-induced intestinal damage and symptoms. Timely market event

$TRAX why this matters - CD122 antagonist blocking IL-15 + IL-2, both drivers of celiac damage IELs are the killers in celiac, ANB033 actually reduced them while pbo +18.83 exploded Gluten-free diet is only option today, no approved drug. Largest autoimmune disease without therapy. Data first, MOA second - this one checks both.

$TRAX worked out well too In 32 evaluable patients, ANB033 limited gut damage on biopsy versus placebo (p=0.009) and blocked symptom spikes through a 14-day gluten challenge, with no serious adverse events. A late-stage celiac trial is eyed for 2027.

$TRAX First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

$TRAX ANB033 Cohort 1 today - CD122 antagonist, gluten-challenge mucosal damage prevention study. First celiac drug with actual mucosal protection readout, not just symptom score. No approved drug for celiac, only diet. If this shows protection, that's a completely new category. 8:30am ET call. Watching for villous height/crypt depth data. Bullish setup into data.

$TRAX Follow-up: First Tracks Biotherapeutics, a clinical-stage autoimmune antibody biotech, is selling 6,106,870 shares at $32.75 in a ~$200M private placement, after an Oct 12 release (8-K, Oct 13) said ANB033 protected against gut damage in a celiac trial. $32.75 is ~4% below the $34.13 close at 16:00 ET Oct 14; the shares add ~17% to 35.73M outstanding; $200M tops $168.0M cash at June 30. In return: ~$200M gross before fees, for general corporate purposes including ANB033 development. Closing expected Oct 19; resale registration to follow.

Canaccord Genuity y'day⬆️ $TRAX's PT to $60 from $50 and reiterated Buy after First Tracks Biotherapeutics announced positive topline data from the Phase Ib trial in celiac disease (CeD). $ENTO $ARGX TEVA TAK SNY CHGCY IMUX EPRX PHAT AZN BMY Canaccord Genuity said -- The readout included data from Cohort I, which was designed to assess the ability of ANB033 to prevent mucosal damage induced from gluten challenge. The data reported today were positive and statistically significant on both histological measures like villous height-to-crypt depth ratio (VHCD) and intraepithelial lymphocytes (IEL) density and also on patient reported symptoms. We reiterate our BUY rating and increase our 12-month PT to $60 to reflect an increased probability estimate of approval for ANB033 in CeD.

$TRAX My last thought here for today...There are few retail following this one and the float is close to 100% institutionally held as this was a spinoff of ANAB. After the spinoff, it got ahead of itself and ran close to $50. This is an excellent opportunity to start a position. Take advantage.

$TRAX This is impressive data that puts a new floor under the stock price. Will back and fill as it grinds its way back to the $50 high. Time to build positions. Going much higher.

$TRAX heavily owned by mms I’m hoping they short it down to 25 at least before next readout I’d like to have 5000 shares by then

$TRAX guess I’ll wait a few weeks 😭😂 to see if we get a pullback before I have to average up

$TRAX: First Tracks Biotherapeutics announced ANB033 met key Phase 1b celiac disease endpoints, significantly reducing intestinal damage and preventing symptom worsening.

$TRAX First Tracks Biotherapeutics, a clinical-stage autoimmune antibody biotech spun out of AnaptysBio, said ANB033 protected against gut damage vs placebo in a 32-patient celiac gluten challenge: Vh:Cd ratio -0.17 vs -0.66 (p=0.009), no serious adverse events. At the Oct 9 close of $31.79, 35.39M shares are worth about $1.1B, vs $168.0M cash at June 30 and runway guided into Q2 2028. Caveat: this was a small 6-week prevention test. Data from the healing cohort (Cohort 2) is due Q1 2027, and a late-stage trial is planned for 2027.

$TRAX is trading sharply higher on clinical trial results following a Globe Newswire release. First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease, showing statistically significant protection against gluten-induced intestinal damage and symptoms with a favorable safety pr RTPR pushed this release out to users at 7:00:00 AM ET